TET2 and myeloproliferative neoplasm: PDXs recapitulated classical phenotypes of the patients from which they were derived (WBC, HCT, splenomegaly; Figure 2D–F) and served as a relevant platform to observe how different MPN subtypes support the expansion of independent TET2- and TP53-mutant clones.